Volunteer Assignments and Opportunities: Difference between revisions

[checked revision][checked revision]
No edit summary
No edit summary
Line 2,583: Line 2,583:
|Astrocystoma, IDH-Mutant
|Astrocystoma, IDH-Mutant
|Disease
|Disease
|Riley Lochner (trainee), Shashi Shetty (mentor)
|3/3/2022
|
|
|PENDING
|
|
|Laveniya Satgunaseelan (LS)
|
|
|
|2021 template added
|
|
|
|
|-
|-
|Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted||Disease||
|Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted||Disease||Riley Lochner (trainee), Shashi Shetty (mentor)
|
|3/3/2022
|
|
|
|
|
|PENDING
|
|
|Laveniya Satgunaseelan (LS)
|
|
|2021 template added
|-
|-
|Glioblastoma, IDH-Wildtype||Disease||
|Glioblastoma, IDH-Wildtype||Disease||
Line 2,646: Line 2,646:
|
|
|-
|-
|Diffuse Midline Glioma, H3  K27-Altered||Disease||
|Diffuse Midline Glioma, H3  K27-Altered||Disease||Laveniya Satgunaseelan (Linda Cooley - previous version)
|
|
|
|
|
|
|
|PENDING
|
|
|LS
|
|
|2021 template added
|-
|-
|Diffuse Hemispheric Glioma, H3 G34-Mutant||Disease||
|Diffuse Hemispheric Glioma, H3 G34-Mutant||Disease||Xiaolin (Lynn) Hu
|
|2/21/2022
|
|
|
|
|
|PENDING
|
|
|LS
|
|
|2021 template added
|-
|-
|Diffuse Paediatric-Type High-Grade Glioma, H3-Wildtype and IDH-Wildtype||Disease||
|Diffuse Paediatric-Type High-Grade Glioma, H3-Wildtype and IDH-Wildtype||Disease||Madina Sukhanova
|
|10/28/2022
|
|
|
|
|
|PENDING
|
|
|LS
|
|
|2021 template added
|-
|-
|Infant-Type Hemispheric Glioma||Disease||
|Infant-Type Hemispheric Glioma||Disease||
Line 2,680: Line 2,680:
|
|
|
|
|
|2021 template added
|-
|-
|Pilocytic Astrocytoma||Disease||
|Pilocytic Astrocytoma||Disease||Jeremy Pulvers
|
|9/13/2022<br />
|
|
|
|
|
|PENDING
|
|
|LS
|
|
|2021 template added
|-
|-
|High-Grade Astrocytoma with Piloid Features||Disease||
|High-Grade Astrocytoma with Piloid Features||Disease||
Line 2,736: Line 2,736:
|
|
|-
|-
|Ganglioglioma||Disease||
|Ganglioglioma||Disease||Leila Moayed-Aloei
|
|6/30/2022
|
|
|
|
|
|COMPLETE
|
|
|LS
|
|
|2021 template added
|-
|-
|Gangliocytoma||Disease||
|Gangliocytoma||Disease||
Line 2,979: Line 2,979:
|
|
|-
|-
|Medulloblastoma, WNT-Activated||Disease||
|Medulloblastoma, WNT-Activated||Disease||Lisa Lansdon, PhD (LGG trainee just finished), Midhat Farooqi, MD (mentor), Children's Mercy Hospital Kansas City
|
|9/20/21
|
|
|
|
|
|
|COMPLETE
|
|
|Holli Drendel (interim)/Laveniya Satgunaseelan (LS)
|9/22/2022
|2021 template added
|-
|-
|Medulloblastoma, SHH-Activated and TP53-Wildtype||Disease||
|Medulloblastoma, SHH-Activated and TP53-Wildtype||Disease||